Genetics

In a Spanish MS cohort, a common CD46 variant (rs2724385) and the way CD46 mRNA shifts during the first year of therapy tracked with response to interferon-β: patients with the TT genotype tended to do better, while those whose CD46 levels rose over time were less likely to meet the “no relapses, no progression” mark at 12 months. It’s an early but intriguing pharmacogenomic signal—pointing to how complement regulation and immune tuning could help personalize MS treatment—yet it still needs replication before guiding clinical decisions.